Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding
about
Human cytomegalovirus resistance to antiviral drugsAntiviral drug resistance of human cytomegalovirus.Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27Viral and cell cycle-regulated kinases in cytomegalovirus-induced pseudomitosis and replication.Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavirMaribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adultsFast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient.In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.Development of new antivirals for herpesviruses.Antivirals and antiviral strategies.Overview of congenitally and perinatally acquired cytomegalovirus infections: recent advances in antiviral therapy.Synthesis and anti-HIV activity of (-)-beta-D-(2R,4R)-1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (-)-beta-D-(2R,4R)-1,3-dioxolane guanosine (DXG) prodrugs.Human cytomegalovirus protein kinase UL97 forms a complex with the tegument phosphoprotein pp65Update on new antivirals under development for the treatment of double-stranded DNA virus infectionsAccelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.Conserved herpesvirus protein kinases.Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.Advances in the antiviral therapy of herpes virus infection in children.Protein array identification of substrates of the Epstein-Barr virus protein kinase BGLF4Maribavir: a novel antiviral agent with activity against cytomegalovirus.Human papillomavirus 16 E7 inactivator of retinoblastoma family proteins complements human cytomegalovirus lacking UL97 protein kinase.Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir.Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms.Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections.Activities of benzimidazole D- and L-ribonucleosides in animal models of cytomegalovirus infections.The search for new therapies for human cytomegalovirus infections.Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents.Phosphorylation events during viral infections provide potential therapeutic targets.Comprehensive Review in Current Developments of Benzimidazole-Based Medicinal Chemistry.Letermovir Treatment of Human Cytomegalovirus Infection Antiinfective Agent.The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egressPhase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects.Maribavir inhibits epstein-barr virus transcription in addition to viral DNA replicationNovel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity.Treatment of alpha and beta herpesvirus infections in solid organ transplant recipients.Effect of cell culture conditions on the anticytomegalovirus activity of maribavir.Human cytomegalovirus UL27 is not required for viral replication in human tissue implanted in SCID miceDiverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivoNucleoside analogues exerting antiviral activity through a non-nucleoside mechanism.
P2860
Q24556634-E700BFF9-BE4C-4647-AEBB-C7650D713DE1Q30430427-DDB80728-E776-4263-8E89-939D42BB3884Q31011523-A6B93B87-1DF6-4EA6-8DB4-E90D44463A1DQ33268403-5FB1AE1B-D237-4A6B-AB80-F9E19EBD3AFFQ34437391-33493A33-D54E-4A36-B716-FC5236F05737Q34510611-A7C5A10E-6D35-4BFD-AF99-AA44A25125A3Q34841085-D506C16C-59D5-4E0D-9F58-049985493CF1Q35103227-BA694B39-756C-43A3-AA2E-4CBE38493DEAQ35669533-1BB32FE6-CB4C-44F7-886B-DB9D86BC066AQ35889586-31C7A767-97EE-4AA0-9E29-D84EDAB5A230Q35917421-736C7897-08B8-49EA-94B0-22CA6D3AB7E1Q36069767-5D5A5081-C02E-41F7-B349-44837FC95AE9Q36099029-9C759229-C052-4C46-8E0F-30207DCBE0A1Q36185647-33F15899-5C85-405B-AA5D-D711DA55991EQ36423920-3F7E8F6B-6140-4B27-B44F-8F8E42B4DC78Q36491044-4DCCFF6E-6F33-41EA-95E6-974634F12A0EQ36593846-E370CDDC-A9D8-4736-9B4C-D71C48EA79B9Q36688958-270C0E5F-284C-4CAC-9B96-0039AE562FE4Q37192108-64E64DEA-9930-4AB5-8061-A9B305461F02Q37242251-37AD8FC3-3614-4F75-BA5A-4369364C2411Q37377351-733AE1B2-3F18-4C5B-B3D2-119B59090EA8Q37478310-6B85E430-5CE2-4F5E-A74D-DDDC6633829AQ37568962-79823C88-4777-4F65-89D7-747EEFC31385Q37624896-7EAD7E36-5618-4874-A04E-8114C1E57633Q37734561-148DF7CB-581F-4542-9EC8-7CEA88CE03A7Q37811458-2773731D-0601-447D-AE5A-49A9C569C8D5Q37951633-EE3F510A-3F3B-4866-B28E-8B1AAA9821A4Q37960427-6D81B0A4-0145-43D5-B003-ECFBA201ACD9Q38263434-F1D28627-25A4-47A1-83F3-5B41C6BC36EEQ39325580-5FB5DC0A-2784-4C88-9732-70A8663C4F12Q39699217-16750EEF-C996-4ED2-BFF2-EAB7697F9F0AQ39743346-9EEE83ED-6619-4F60-BB1A-385B8F61664DQ39798789-3E55F4A0-8851-49D9-B914-072741F9763DQ40289512-D7DC0542-227F-4D9C-B547-CF063A9C6732Q40426465-CA477A57-4495-40EC-9701-377B2FAE776CQ41473772-51323B17-4565-4DDE-A28A-BFA880394820Q41818018-7CFFC850-8969-460F-83A9-CE6FC8D32FA1Q41893150-BD98B9AD-CBE9-47A7-9672-488C4B04F967Q42141568-D610DB61-4EDD-42FF-94F9-458E079AE00BQ44813648-16E9A5F7-57E1-4EE8-A213-A272052F2B30
P2860
Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Phase I dose escalation trial ...... ith asymptomatic HCMV shedding
@en
Phase I dose escalation trial ...... th asymptomatic HCMV shedding.
@nl
type
label
Phase I dose escalation trial ...... ith asymptomatic HCMV shedding
@en
Phase I dose escalation trial ...... th asymptomatic HCMV shedding.
@nl
prefLabel
Phase I dose escalation trial ...... ith asymptomatic HCMV shedding
@en
Phase I dose escalation trial ...... th asymptomatic HCMV shedding.
@nl
P2093
P2860
P1476
Phase I dose escalation trial ...... ith asymptomatic HCMV shedding
@en
P2093
Christine L Talarico
Jacob P Lalezari
Judith A Aberg
Laurene H Wang
Mark A Jacobson
Mary Beth Wire
Richard Miner
Shuching Shaw
W Lawrence Drew
Wendy Snowden
P2860
P304
P356
10.1128/AAC.46.9.2969-2976.2002
P407
P577
2002-09-01T00:00:00Z